LivaNova (LIVN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
The annual general meeting (AGM) will be held virtually on June 10, 2026, with shareholders of record as of April 13, 2026, eligible to vote on key proposals, including director elections, executive compensation, auditor appointments, share allotment, pre-emption rights, share repurchase contracts, and remuneration reports.
Eleven directors are nominated for election, all standing for one-year terms, with a focus on diversity, independence, and relevant expertise; the board is unclassified and uses majority voting in uncontested elections.
Shareholders will vote on advisory resolutions for U.S. executive compensation (say-on-pay) and the UK directors' remuneration report, as well as ratification of PwC as both U.S. and UK auditors, and authorization for the board to determine auditor remuneration.
Proposals include granting authority to allot shares, disapply pre-emption rights, approve share repurchase contracts and counterparties, and receive and adopt the UK annual report and accounts.
Voting matters and shareholder proposals
Proposals cover director elections, say-on-pay, auditor ratification, share allotment, pre-emption rights, share repurchase contracts, remuneration reports, and adoption of annual accounts.
All proposals are recommended for approval by the board, with most requiring a simple majority, except the special resolution on pre-emption rights, which requires 75%.
Shareholders may submit proposals for the 2027 AGM by December 30, 2026, and director nominations must follow specific procedures.
Board of directors and corporate governance
Ten of eleven directors are independent; the board is diverse in gender and ethnicity, with a mix of tenures and backgrounds.
The board conducts annual self-evaluations, reviews governance documents, and separates the roles of CEO and independent chair.
Three standing committees (Audit and Compliance, Compensation and Human Capital Management, Nominating and Corporate Governance) are composed entirely of independent directors.
Directors are subject to meaningful equity ownership requirements and prohibited from hedging or pledging company stock.
Shareholder engagement is emphasized, with regular outreach to top shareholders and opportunities for communication with the board.
Latest events from LivaNova
- AGM to address director elections, compensation, auditor matters, and share capital authorities.LIVN
Proxy filing29 Apr 2026 - Double-digit 2025 growth and margin gains set stage for 6–7% revenue growth in 2026.LIVN
Q4 202525 Feb 2026 - Q2 revenue up 10% and adjusted EPS up, with raised 2024 guidance and strong segment growth.LIVN
Q2 20242 Feb 2026 - Twelve key resolutions were presented and 89% of voting rights were represented.LIVN
AGM 20241 Feb 2026 - Core growth, innovation in DTD/OSA, and margin expansion drive a multi-year growth outlook.LIVN
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Sustained growth driven by talent, innovation, and strategic execution, with a 2030 vision.LIVN
Baird 2024 Global Healthcare Conference21 Jan 2026 - Q3 2024 revenue up 11.2%, margins expand, and guidance raised on strong segment growth.LIVN
Q3 202417 Jan 2026 - OSA market entry and reimbursement gains drive growth, with profitability targeted by 2029.LIVN
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - Strong core growth, promising OSA trial, and strategic R&D shifts support future expansion.LIVN
Stifel 2024 Healthcare Conference13 Jan 2026